Ascendis Pharma A/S
ASND- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001612042
In the last 90 days, Ascendis Pharma A/S insiders filed 1 open-market purchase and 2 sales; 313 institutions reported holding it in 13F filings for Q2 2026, worth $17.8B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Ascendis Pharma A/S insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 1 filing
- 1 insider, $492.7K in total
- Open-market sells
- 2 filings
- 2 insiders, $872.9K in total
- Insiders trading
- 3
- Net value
- −$380.3K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Ascendis Pharma A/S, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Bodenhoff Mads | SVP & PAO | 0 | Sep 9, 2026 | 1 |
| Holtug Lars | Director | 4,000 | Sep 3, 2026 | 1 |
| Bienaime Jean Jacques | Director | 2,900 | Aug 18, 2026 | 3 |
| Smith Scott Thomas | EVP & Chief Financial Officer | 4,367 | Jun 2, 2026 | 2 |
| Jensen Flemming Steen | See Remarks | 0 | May 12, 2026 | 1 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 9, 2026 (view filing)5:04 PM ET | Sep 8 | 1 day | Bodenhoff MadsSVP & PAO | SSale | −3.00K | $270.19 | −$810.6K | −100.0%0 after | |
| Sep 3, 2026 (view filing)4:09 PM ET | Sep 2 | 1 day | Holtug LarsDirector | SSale | −236 | $264.13 | −$62.3K | −5.6%4.00K after | |
| Aug 18, 2026 (view filing)9:02 PM ET | Aug 14 | 4 days | Bienaime Jean JacquesDirector | PPurchase | +2.00K | $246.33 | +$492.7K | +222.2%2.90K after | 2 lots |
| Jun 2, 2026 (view filing) | Jun 2 | Same day | Smith Scott ThomasEVP & Chief Financial Officer | PPurchase | +100 | $219.00 | +$21.9K | +2.3%4.37K after | |
| Jun 1, 2026 (view filing) | May 29 | 3 days | Bienaime Jean JacquesDirector | PPurchase | +500 | $223.12 | +$111.6K | +125.0%900 after | 3 lots |
| Jun 1, 2026 (view filing) | May 29 | 3 days | Smith Scott ThomasEVP & Chief Financial Officer | PPurchase | +250 | $223.32 | +$55.8K | +6.2%4.27K after | |
| May 27, 2026 (view filing) | May 26 | 1 day | Bienaime Jean JacquesDirector | PPurchase | +400 | $237.81 | +$95.1K | New position400 after | 2 lots |
| May 12, 2026 (view filing) | May 11 | 1 day | Jensen Flemming SteenSee Remarks | SSale | −19.5K | $238.49 | −$4.64M | −100.0%0 after |